INFECTIOUS COMPLICATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED WITH ANTI-PD(L)1 IMMUNE CHECKPOINT INHIBITORS

被引：1
|
作者：
Guo, Matthew [1 ]
Balaji, Aanika [1 ]
Murray, Joseph [1 ]
Reuss, Joshua [2 ]
Steinke, Seema Mehta [3 ]
Naidoo, Jarushka [4 ,5 ]
机构：
[1] Johns Hopkins Sch Med, Baltimore, MD USA
[2] Georgetown Univ, Washington, DC USA
[3] Johns Hopkins Sch Med Univ, Pittsburgh Sch Med, Pittsburgh, PA USA
[4] Johns Hopkins Sch Med, Beaumont Hosp, Baltimore, MD USA
[5] Univ Hlth Sci, Royal Coll Surg Ireland, Dublin, Ireland
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.237
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
237
引用
收藏
页码：A253 / A253
页数：1
相关论文
共 50 条
  • [1] Infectious Complications in Patients With Non-small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
    Guo, Matthew Z.
    Balaji, Aanika
    Murray, Joseph C.
    Reuss, Joshua E.
    Steinke, Seema Mehta
    Bennett, Kathleen
    Naidoo, Jarushka
    CLINICAL LUNG CANCER, 2023, 24 (07) : 613 - 620
  • [2] Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors
    Hara, Naofumi
    Ichihara, Eiki
    Harada, Daijiro
    Inoue, Koji
    Fujiwara, Keiichi
    Hosokawa, Shinobu
    Kishino, Daizo
    Haruyuki, Kawai
    Ochi, Nobuaki
    Oda, Naohiro
    Hotta, Katsuyuki
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (12) : 3749 - 3755
  • [3] Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors
    Naofumi Hara
    Eiki Ichihara
    Daijiro Harada
    Koji Inoue
    Keiichi Fujiwara
    Shinobu Hosokawa
    Daizo Kishino
    Kawai Haruyuki
    Nobuaki Ochi
    Naohiro Oda
    Katsuyuki Hotta
    Yoshinobu Maeda
    Katsuyuki Kiura
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 3749 - 3755
  • [4] Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1
    Cabezon-Gutierrez, Luis
    Custodio-Cabello, Sara
    Palka-Kotlowska, Magda
    Alonso-Viteri, Soledad
    Khosravi-Shahi, Parham
    CLINICAL LUNG CANCER, 2021, 22 (05) : 381 - 389
  • [5] Immune-related pneumonitis in non-small cell lung cancer (NSCLC) patients treated with anti-PD(L)1: the impact of previous thoracic radiotherapy
    Botticella, A.
    Ibrahim, T.
    Mezquita, L.
    Hendriks, L.
    Le Pavec, J.
    Ferrara, R.
    Caramella, C.
    Remon, J.
    Champiat, S.
    Michot, J. M.
    Lavaud, P.
    Aboubakar, F.
    Gustin, P.
    David, P.
    Gazzah, A.
    Marabelle, A.
    Deutsch, E.
    Besse, B.
    Le Pechoux, C.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E75 - E75
  • [6] Incidence of Cardiotoxicity in Patients Treated for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
    Carpenter, I. N.
    Brice, K. B.
    Walker, D.
    Dumais, K.
    Alvarez, A. M.
    Cohen, N. S.
    Raez, L. E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S629 - S629
  • [7] PD-L1, brain metastases, and survival among patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.
    Feisal, James
    Balakrishna, Pragathi
    Itani, Aleena
    King, Caleb
    Acharya, Pawan
    Vesely, Sara
    Aljumaily, Raid
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Immune checkpoint inhibitors in non-small cell lung cancer
    Eberhardt, Wilfried Ernst Erich
    ONKOLOGE, 2017, 23 (10): : 838 - 844
  • [9] Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Herzberg, Benjamin
    Campo, Meghan J.
    Gainor, Justin F.
    ONCOLOGIST, 2017, 22 (01): : 81 - 88
  • [10] Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1
    Shao, Min-min
    Xu, Yue-ping
    Zhang, Jin-jing
    Mao, Mao
    Wang, Meng-chuan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (06): : 1446 - 1458
12345